Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib

T. Hrdinova, O. Toman, J. Dresler, J. Klimentova, B. Salovska, P. Pajer, O. Bartos, V. Polivkova, J. Linhartova, K. Machova Polakova, H. Kabickova, B. Brodska, M. Krijt, J. Zivny, D. Vyoral, J. Petrak

. 2021 ; 58 (2) : 238-250. [pub] 20201223

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004647

Chronic myeloid leukemia (CML) is a malignant hematopoietic disorder distinguished by the presence of a BCR‑ABL1 fused oncogene with constitutive kinase activity. Targeted CML therapy by specific tyrosine kinase inhibitors (TKIs) leads to a marked improvement in the survival of the patients and their quality of life. However, the development of resistance to TKIs remains a critical issue for a subset of patients. The most common cause of resistance are numerous point mutations in the BCR‑ABL1 gene, followed by less common mutations and multiple mutation-independent mechanisms. Recently, exosomes, which are extracellular vesicles excreted from normal and tumor cells, have been associated with drug resistance and cancer progression. The aim of the present study was to characterize the exosomes released by imatinib‑resistant K562 (K562IR) cells. The K562IR‑derived exosomes were internalized by imatinib‑sensitive K562 cells, which thereby increased their survival in the presence of 2 µM imatinib. The exosomal cargo was subsequently analyzed to identify resistance‑associated markers using a deep label‑free quantification proteomic analysis. There were >3,000 exosomal proteins identified of which, 35 were found to be differentially expressed. From this, a total of 3, namely the membrane proteins, interferon‑induced transmembrane protein 3, CD146 and CD36, were markedly upregulated in the exosomes derived from the K562IR cells, and exhibited surface localization. The upregulation of these proteins was verified in the K562IR exosomes, and also in the K562IR cells. Using flow cytometric analysis, it was possible to further demonstrate the potential of CD146 as a cell surface marker associated with imatinib resistance in K562 cells. Taken together, these results suggested that exosomes and their respective candidate surface proteins could be potential diagnostic markers of TKI drug resistance in CML therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004647
003      
CZ-PrNML
005      
20220127145106.0
007      
ta
008      
220113s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ijo.2020.5163 $2 doi
035    __
$a (PubMed)33491750
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Hrdinova, Tereza $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
245    10
$a Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib / $c T. Hrdinova, O. Toman, J. Dresler, J. Klimentova, B. Salovska, P. Pajer, O. Bartos, V. Polivkova, J. Linhartova, K. Machova Polakova, H. Kabickova, B. Brodska, M. Krijt, J. Zivny, D. Vyoral, J. Petrak
520    9_
$a Chronic myeloid leukemia (CML) is a malignant hematopoietic disorder distinguished by the presence of a BCR‑ABL1 fused oncogene with constitutive kinase activity. Targeted CML therapy by specific tyrosine kinase inhibitors (TKIs) leads to a marked improvement in the survival of the patients and their quality of life. However, the development of resistance to TKIs remains a critical issue for a subset of patients. The most common cause of resistance are numerous point mutations in the BCR‑ABL1 gene, followed by less common mutations and multiple mutation-independent mechanisms. Recently, exosomes, which are extracellular vesicles excreted from normal and tumor cells, have been associated with drug resistance and cancer progression. The aim of the present study was to characterize the exosomes released by imatinib‑resistant K562 (K562IR) cells. The K562IR‑derived exosomes were internalized by imatinib‑sensitive K562 cells, which thereby increased their survival in the presence of 2 µM imatinib. The exosomal cargo was subsequently analyzed to identify resistance‑associated markers using a deep label‑free quantification proteomic analysis. There were >3,000 exosomal proteins identified of which, 35 were found to be differentially expressed. From this, a total of 3, namely the membrane proteins, interferon‑induced transmembrane protein 3, CD146 and CD36, were markedly upregulated in the exosomes derived from the K562IR cells, and exhibited surface localization. The upregulation of these proteins was verified in the K562IR exosomes, and also in the K562IR cells. Using flow cytometric analysis, it was possible to further demonstrate the potential of CD146 as a cell surface marker associated with imatinib resistance in K562 cells. Taken together, these results suggested that exosomes and their respective candidate surface proteins could be potential diagnostic markers of TKI drug resistance in CML therapy.
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a antigen CD146 $x metabolismus $7 D051929
650    _2
$a antigeny CD36 $x metabolismus $7 D018955
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a chemorezistence $7 D019008
650    _2
$a exozómy $x účinky léků $x metabolismus $7 D055354
650    _2
$a bcr-abl fúzní proteiny $x antagonisté a inhibitory $x genetika $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x farmakologie $x terapeutické užití $7 D000068877
650    _2
$a buňky K562 $7 D020014
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $x patologie $7 D015464
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    _2
$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428
650    _2
$a proteiny vázající RNA $x metabolismus $7 D016601
655    _2
$a časopisecké články $7 D016428
700    1_
$a Toman, Ondrej $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Dresler, Jiri $u Military Health Institute, Military Medical Agency, 160 01 Prague 6, Czech Republic
700    1_
$a Klimentova, Jana $u Faculty of Military Health Sciences, University of Defense in Brno, 500 02 Hradec Kralove, Czech Republic
700    1_
$a Salovska, Barbora $u Department of Genome Integrity, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague 4, Czech Republic
700    1_
$a Pajer, Petr $u Military Health Institute, Military Medical Agency, 160 01 Prague 6, Czech Republic
700    1_
$a Bartos, Oldrich $u Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, 169 02 Prague 6, Czech Republic
700    1_
$a Polivkova, Vaclava $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Linhartova, Jana $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Kabickova, Hana $u Military Health Institute, Military Medical Agency, 160 01 Prague 6, Czech Republic
700    1_
$a Brodska, Barbora $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Krijt, Matyas $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Zivny, Jan $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 20 Prague 2, Czech Republic
700    1_
$a Vyoral, Daniel $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
700    1_
$a Petrak, Jiri $u Institute of Hematology and Blood Transfusion, 128 20 Prague 2, Czech Republic
773    0_
$w MED00002350 $t International journal of oncology $x 1791-2423 $g Roč. 58, č. 2 (2021), s. 238-250
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33491750 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145103 $b ABA008
999    __
$a ok $b bmc $g 1751954 $s 1155796
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 58 $c 2 $d 238-250 $e 20201223 $i 1791-2423 $m International journal of oncology $n Int J Oncol $x MED00002350
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace